Evidence map›Paper›PMID 19173720›Full record

ArticleBMC immunology2009

Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants.

Marta Barreto, Ricardo C Ferreira, Lara Lourenço, Maria F Moraes-Fontes, Eugénia Santos, Miguel Alves, Cláudia Carvalho, Berta Martins, Rita Andreia, João F Viana and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Effect ofInternational journal of rheumatology · 2017
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Modulation of tolerogenic dendritic cells and autoimmunity.Seminars in cell & developmental biology · 2015
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Marta BarretoInstituto Gulbenkian de Ciência, Rua da Quinta Grande, 6 2780-156 Oeiras, Portugal. mbarreto@igc.gulbenkian.pt
Ricardo C Ferreira
Lara Lourenço
Maria F Moraes-Fontes
Eugénia Santos
Miguel Alves
Cláudia Carvalho
Berta Martins
Rita Andreia
João F Viana
Carlos Vasconcelos
Luísa Mota-Vieira
Carlos Ferreira
Jocelyne Demengeot
Astrid M Vicente
Instituto Gulbenkian de Ciência · PTHospital de Santa Maria · PTUniversidade do Porto · PTHospital do Divino Espírito Santo · PTNational Institute of Health Dr. Ricardo Jorge · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD4+CD25+ regulatory T cells play an essential role in maintaining immune homeostasis and preventing autoimmunity. Therefore, defects in Treg development, maintenance or function have been associated with several human autoimmune diseases including Systemic Lupus Erythematosus (SLE), a systemic autoimmune disease characterized by loss of tolerance to nuclear components and significantly more frequent in females.

resultsTo investigate the involvement of Treg in SLE pathogenesis, we determined the frequency of CD4+CD25+CD45RO+ T cells, which encompass the majority of Treg activity, in the PBMC of 148 SLE patients (76 patients were part of 54 families), 166 relatives and 117 controls. SLE patients and their relatives were recruited in several Portuguese hospitals and through the Portuguese Lupus Association. Control individuals were blood donors recruited from several regional blood donor centers. Treg frequency was significantly lower in SLE patients than healthy controls (z = -6.161, P < 0.00001) and intermediate in the relatives' group. Remarkably, this T cell subset was also lower in females, most strikingly in the control population (z = 4.121, P < 0.001). We further ascertained that the decreased frequency of Treg in SLE patients resulted from the specific reduction of bona fide FOXP3+CD4+CD25+ Treg. Treg frequency was negatively correlated with SLE activity index (SLEDAI) and titers of serum anti-dsDNA antibodies. Both Treg frequency and disease activity were modulated by IVIg treatment in a documented SLE case. The segregation of Treg frequency within the SLE families was indicative of a genetic trait. Candidate gene analysis revealed that specific variants of CTLA4 and TGFbeta were associated with the decreased frequency of Treg in PBMC, while FOXP3 gene variants were associated with affection status, but not with Treg frequency.

conclusionSLE patients have impaired Treg production or maintenance, a trait strongly associated with SLE disease activity and autoantibody titers, and possibly resulting from the inability to convert FOXP3+CD25- into FOXP3+CD25+ T cells. Treg frequency is highly heritable within SLE families, with specific variants of the CTLA4 and TGFbeta genes contributing to this trait, while FOXP3 contributes to SLE through mechanisms not involving a modulation of Treg frequency. These findings establish that the genetic components in SLE pathogenesis include genes related to Treg generation or maintenance.

Indexed as

Age FactorsAntibodies, AntinuclearAntigens, CDCD4 AntigensCTLA-4 AntigenFemaleForkhead Transcription FactorsGenotypeHumansInterleukin-2Interleukin-2 Receptor alpha SubunitLeukocyte Common AntigensLupus Erythematosus, SystemicMalePolymorphism, GeneticQuantitative Trait, HeritableAntibodies, AntinuclearAntigens, CDCD4 AntigensCTLA-4 AntigenCTLA4 protein, humanForkhead Transcription FactorsFOXP3 protein, humanInterleukin-2Interleukin-2 Receptor alpha SubunitLeukocyte Common AntigensTransforming Growth Factor beta

Identifiers

PMID19173720
PMCPMC2656467
OpenAlexW2149076437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.